Compound for preventing or treating autoimmune diabetes and preparation method and application thereof

An autoimmune and compound technology, applied in the direction of steroids, allergic diseases, medical preparations containing active ingredients, etc., to achieve the effect of preventing or treating autoimmune diabetes

Inactive Publication Date: 2012-10-03
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF2 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no report on the preparation of diosgenin, ibu

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound for preventing or treating autoimmune diabetes and preparation method and application thereof
  • Compound for preventing or treating autoimmune diabetes and preparation method and application thereof
  • Compound for preventing or treating autoimmune diabetes and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 12

[0037] Example 12 - Preparation of Diosgenin Acetoxybenzoate (Compound 2):

[0038] (1) Preparation of 2-acetoxybenzoyl chloride:

[0039]

[0040] In a 50ml reaction vial, add aspirin (4.50g, 25mmol), 2 drops of N,N'-dimethylformamide (DMF) and 3ml of thionyl chloride SOCl 2 (36mmol), quickly connect the spherical condenser (calcium chloride drying tube is installed on the top), and import the tail gas into the sodium hydroxide solution for absorption. Slowly heat up to 70°C under stirring, and keep this temperature constant until no bubbles emerge from the tail gas end. Remove excess thionyl chloride by suction filtration under reduced pressure to obtain light yellow oily liquid, namely 2-acetoxybenzoyl chloride. (TLC: chloroform:methanol=9:1, R f =0.83); Dissolve 2-acetoxybenzoyl chloride in tetrahydrofuran THF to make 25ml of liquid, and seal it for later use.

[0041] (2) Preparation of diosgenin 2-acetoxybenzoate:

[0042]

[0043] Into a 150ml three-necked fl...

Embodiment 2

[0044] Example 2 Preparation of N-(2-acetoxybenzoyl)-glycine diosgenin ester (compound 3)

[0045] (1) Preparation of 2-acetoxybenzoyl chloride:

[0046]

[0047]In a 50ml reaction bottle, add 4.50g (25mmol) of aspirin, 2 drops of N,N'-dimethylformamide DMF and 3ml of thionyl chloride SOCl 2 (36mmol), quickly connect the spherical condenser (calcium chloride drying tube is installed on the top), and import the tail gas into the sodium hydroxide solution for absorption. Slowly heat up to 70°C under stirring, and keep this temperature constant until no bubbles emerge from the tail gas end. Excess thionyl chloride was removed by suction filtration under reduced pressure to obtain 2-acetoxybenzoyl chloride as an oily liquid. (Chloroform:methanol=9:1, Rf=0.83; dissolve 2-acetoxybenzoyl chloride in tetrahydrofuran THF to make 25ml of liquid, sealed for later use)

[0048] (2) Preparation of N-tert-butoxycarbonylglycine diosgenin ester

[0049]

[0050] In a 50ml reaction b...

Embodiment 32

[0057] Example 32- Preparation of (4-isobutylphenyl) diosgenin propionate (compound 4):

[0058]

[0059] 1.03g (5mmol) of ibuprofen, 2.07g (5mmol) of diosgenin, 1g of 4A molecular sieve, 122mg (1mmol) of 4-dimethylaminopyridine DMAP, 172mg (0.2mmol) of p-toluenesulfonic acid TsOH, 100ml of anhydrous dichloromethane, add dropwise N,N'-dicyclohexylcarbodiimide DCC 1.55g (7.5mmol, dissolved in 50ml of anhydrous dichloromethane) under stirring at room temperature, and check the progress of the reaction by TLC until the reaction is no longer Go, filter. After the filtrate was washed several times with 10g / L citric acid solution and saturated sodium chloride solution successively, it was washed with anhydrous sodium sulfate Na 2 SO 4 Dry and separate on a silica gel column to obtain diosgenin 2-(4-isobutylphenyl)propionate as a white solid, 2.14 g. (Petroleum ether: ethyl acetate=4:1, Rf=0.68) 1H NMR (400MHz, CDCl3) δ7.20(d, J=7.8Hz, 2H), 7.08(d, J=7.7Hz, 2H), 5.34 (dd,J=15....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a compound for preventing or treating autoimmune diabetes, and the structure of the compound is shown in a general formula 1. The invention also discloses a preparation method and an application of the compound. The twin drug compound of diosgenin and ibuprofen or aspirin provided by the invention not only can effectively prevent or treat autoimmune diabetes caused by the damage of beta cells of pancreas islet, but also has better effects of anti-inflammation, analgesia and the like, and a new choice is provided for clinical medication.

Description

technical field [0001] The invention relates to a compound for preventing or treating autoimmune diabetes and its preparation method and application, belonging to the field of medicine. Background technique [0002] Autoimmune diabetes mainly includes type 1 diabetes mellitus (T1DM) and latent autoimmune diabetes of adults (LADA). Among them, type 1 diabetes is an autoimmune disease mediated by T cells. It is based on genetics. Under the action of certain environmental factors, it induces the autoimmune response of pancreatic β cells with the pathological characteristics of insulitis, and damages β cells. It loses the function of synthesizing and secreting insulin, causing glucose metabolism disorder. Latent autoimmune diabetes in adults, its initial clinical manifestations are similar to type 2 diabetes, but the pathogenesis and outcome are the same as those of T1DM, and the difference from T1DM is that the immune damage of the islet β cells of LADA develops slowly. After...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07J71/00A61K31/625A61K31/58A61P29/00A61P3/10A61P37/02
Inventor 黄文何杨吴晓华陆燕蓉程惊秋
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap